Welcome to our dedicated page for EBACU news (Ticker: EBACU), a resource for investors and traders seeking the latest updates and insights on EBACU stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect EBACU's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of EBACU's position in the market.
European Biotech Acquisition Corp. received a notice from Nasdaq on May 28, 2021, due to its failure to file its Quarterly Report for Q1 2021 on time. The company must submit a compliance plan within 60 days and may regain compliance within 180 days by filing the overdue report. The notice does not affect the current trading status of the company's securities, which will continue to trade under the symbols EBAC, EBACU, and EBACW. The company is also evaluating whether to restate its previously issued financial statements due to recent guidance from the SEC regarding SPAC warrants.
European Biotech Acquisition Corp. announced the pricing of its initial public offering (IPO) of 10,000,000 units at $10.00 each, expected to trade on Nasdaq under the symbol 'EBACU' starting March 16, 2021. Each unit includes one Class A ordinary share and one-third of a redeemable warrant, with whole warrants exercisable for $11.50 per share. The company aims to focus on the European life sciences industry, having management connections with LSP, a leading healthcare investment firm. Credit Suisse and Kempen & Co are the joint book-running managers for this offering.
